Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...

Governments and tech companies continue to pour money into quantum technology in the hopes of building a supercomputer that can work at speeds we can't yet fathom to solve big problems.

A professor who refused to bow to activist progressives and parrot land acknowledgements has scored a major First Amendment legal victory — after a years-long battle. “I’m not going to be silenced.

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

Fourth graders participate in an introductory lesson on artificial intelligence during a computer applications class at Dr.

On April 28, 2022, at a highly anticipated concert in Spokane, Washington, the musician Paul McCartney astonished his ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...